Sithakom PhusantiKwanhatai ManosudprasitSomnuek SungkanuparphMahidol University2018-12-212019-03-142018-12-212019-03-142017-03-01Journal of the International Association of Providers of AIDS Care. Vol.16, No.2 (2017), 194-20023259582232595742-s2.0-85016127049https://repository.li.mahidol.ac.th/handle/20.500.14594/42845© SAGE Publications. Coinfection of hepatitis B virus (HBV) or hepatitis C virus (HCV) with HIV is common and associated with increased mortality and increased risk of progression to chronic liver disease. We aimed to study long-term liver diseases after initiation of antiretroviral therapy (ART) in HIV-infected patients with and without HBV or HCV coinfection. A retrospective cohort of 92 patients (32 patients with HBV and/or HCV coinfection) was analyzed. Overall mean age was 38.3 years, and 54.3% were males. Immunological and virological responses were similar between the 2 groups (P >.05). During a median follow-up period of 6.1 years, 12 (13.0%) patients had liver diseases. Kaplan-Meier analysis showed that the coinfection group had a significantly higher probability of developing liver diseases after ART (log-rank test, P <.001). Among the subgroup of 32 patients with coinfection, patients who were initiated ART at CD4 count <200 cells/mm3had a higher rate of liver diseases compared to those who were initiated ART at CD4 count ≥200 cells/mm3(42.3% versus 16.7%; P =.004).Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1177/2325957416686838